This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

ASCO-GU, San Fancisco CA, U.S.A, 08-10 February 2018 Font 1200.261 TiP

Phase II trial of afatinib in patients with advanced/metastatic urothelial carcinoma with genetic alterations in ERBB receptors 1–3 who failed on platinum-based chemotherapy

Albert Font, Javier Puente, Daniel Castellano, Francisco X. Real, Miguel Ángel Climent, Aránzazu Gonzalez del Alba, Stéphane Oudard, Federico J. Vazquez Mazon, Rafael Morales Barrera, Juan Antonio Virizuela, Nuria Sala, Begoña Pérez-Valderrama, Xavier Garcia del Muro, Pedro L. Fernandez, Pedro Jares, Iban Aldecoa, Neil Gibson, Josep Serra, Esteban Rodrigo Imedio, Begoña Mellado
1200.261_font_asco-gu 2018

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations

Choudhury N, et al. J Clin Oncol 2016; 34(18):2165–71